# | Title | Journal | Year | Citations |
---|
|
1 | International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Journal of Thrombosis and Haemostasis | 2006 | 6,200 |
2 | Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia | Journal of Thrombosis and Haemostasis | 2020 | 4,792 |
3 | Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients | Journal of Thrombosis and Haemostasis | 2005 | 3,953 |
4 | Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy | Journal of Thrombosis and Haemostasis | 2020 | 3,028 |
5 | Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients | Journal of Thrombosis and Haemostasis | 2010 | 1,921 |
6 | ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 | Journal of Thrombosis and Haemostasis | 2020 | 1,571 |
7 | Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia | Journal of Thrombosis and Haemostasis | 2020 | 1,521 |
8 | Fibrinogen and fibrin structure and functions | Journal of Thrombosis and Haemostasis | 2005 | 1,418 |
9 | Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy | Journal of Thrombosis and Haemostasis | 2007 | 1,371 |
10 | Incidence of venous thromboembolism in hospitalized patients with COVID‐19 | Journal of Thrombosis and Haemostasis | 2020 | 1,273 |
11 | Incidence and mortality of venous thrombosis: a population-based study | Journal of Thrombosis and Haemostasis | 2007 | 1,161 |
12 | Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis | Journal of Thrombosis and Haemostasis | 2020 | 1,116 |
13 | Update of the guidelines for lupus anticoagulant detection | Journal of Thrombosis and Haemostasis | 2009 | 1,074 |
14 | Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor | Journal of Thrombosis and Haemostasis | 2006 | 1,073 |
15 | D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19 | Journal of Thrombosis and Haemostasis | 2020 | 1,028 |
16 | High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients | Journal of Thrombosis and Haemostasis | 2020 | 1,014 |
17 | Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH | Journal of Thrombosis and Haemostasis | 2015 | 963 |
18 | Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial | Journal of Thrombosis and Haemostasis | 2007 | 945 |
19 | Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings | Journal of Thrombosis and Haemostasis | 2006 | 932 |
20 | Protease‐activated receptors in hemostasis, thrombosis and vascular biology | Journal of Thrombosis and Haemostasis | 2005 | 925 |
21 | A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score | Journal of Thrombosis and Haemostasis | 2010 | 913 |
22 | Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis | Journal of Thrombosis and Haemostasis | 2010 | 834 |
23 | The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome | Journal of Thrombosis and Haemostasis | 2020 | 819 |
24 | Neutrophil extracellular traps promote deep vein thrombosis in mice | Journal of Thrombosis and Haemostasis | 2012 | 762 |
25 | Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing | Journal of Thrombosis and Haemostasis | 2014 | 738 |
26 | Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel | Journal of Thrombosis and Haemostasis | 2007 | 676 |
27 | The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage | Journal of Thrombosis and Haemostasis | 2007 | 644 |
28 | ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders | Journal of Thrombosis and Haemostasis | 2010 | 635 |
29 | Thrombopoietin: a tool for understanding thrombopoiesis | Journal of Thrombosis and Haemostasis | 2003 | 623 |
30 | Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration | Journal of Thrombosis and Haemostasis | 2014 | 602 |
31 | Multiple roles of the endothelial cell protein C receptor | Journal of Thrombosis and Haemostasis | 2007 | 590 |
32 | Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study | Journal of Thrombosis and Haemostasis | 2006 | 583 |
33 | Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study | Journal of Thrombosis and Haemostasis | 2008 | 574 |
34 | Definitions in hemophilia: communication from the SSC of the ISTH | Journal of Thrombosis and Haemostasis | 2014 | 572 |
35 | Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19 | Journal of Thrombosis and Haemostasis | 2020 | 570 |
36 | In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor | Journal of Thrombosis and Haemostasis | 2005 | 566 |
37 | The platelet contribution to cancer progression | Journal of Thrombosis and Haemostasis | 2011 | 566 |
38 | Fibrin structure and wound healing | Journal of Thrombosis and Haemostasis | 2006 | 559 |
39 | Thromboinflammation and the hypercoagulability of COVID‐19 | Journal of Thrombosis and Haemostasis | 2020 | 550 |
40 | Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial | Journal of Thrombosis and Haemostasis | 2007 | 543 |
41 | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1 | Journal of Thrombosis and Haemostasis | 2005 | 541 |
42 | Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome | Journal of Thrombosis and Haemostasis | 2010 | 541 |
43 | Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? | Journal of Thrombosis and Haemostasis | 2007 | 509 |
44 | What is all that thrombin for? | Journal of Thrombosis and Haemostasis | 2003 | 490 |
45 | Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes | Journal of Thrombosis and Haemostasis | 2012 | 487 |
46 | A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) | Journal of Thrombosis and Haemostasis | 2006 | 486 |
47 | Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19 | Journal of Thrombosis and Haemostasis | 2020 | 486 |
48 | Platelet functions beyond hemostasis | Journal of Thrombosis and Haemostasis | 2009 | 485 |
49 | International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer | Journal of Thrombosis and Haemostasis | 2013 | 476 |
50 | Coagulopathy in COVID‐19 | Journal of Thrombosis and Haemostasis | 2020 | 476 |